Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of a Novel Therapeutic for Hyperthyroidism

Award Number: R41DK123953
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/17/2019
PERIOD OF PERFORMANCE END DATE: 08/31/2021

Group Awards By:

View Award Description

Development of a Novel Therapeutic for Hyperthyroidism - Graves’ disease (GD) is the most common cause of hyperthyroidism and is caused by stimulation of the thyroid-stimulating hormone receptor (TSHR) by thyroid receptor stimulating antibodies (TSAbs). Treatment of GD involves antithyroid medication therapy, radioactive iodine, and surgery. At the present, few alternative forms of therapy for GD are available or are in development. The ability to block TSHR action may also be of benefit to other conditions, including Graves; orbitopathy (GO) and differentiated thyroid cancer. Thus, there is considerable interest in developing novel treatments to block TSHR action. Recombinant adeno- associated virus (rAAV) therapy has been developed as a viral vector for gene therapy. Several of these clinical trials have taken place at the University of Florida (UF), which is a major center for the study of AAV- based gene therapy. Of the different rAAV that the serotypes that are available, rAAV8 is the preferred vector for vector-mediated immunotherapy studies in rodent models. Although vector-based immunotherapy has been proposed for infectious diseases, we such approaches that target antibody-mediated conditions are limited. In preliminary studies, we identified a commercially available monoclonal antibody that blocks TSAb and thyroid-stimulating hormone (TSH) action. We also developed a rAAV8 construct that expresses this functional antibody. Thus, we hypothesize that the rAAV9-TBAb vector we generated will target and block TSHR activation. In this Phase 1 STTR proposal, we will evaluate the utility of our new therapeutic in blocking TSH receptor activation. In SA 1, we will test the ability of our therapeutic to block the action of TSH in single dose and multidose studies. In SA 2, we will test the ability of our vector to block the activity of administered TSAbs and a validated murine model of GD. To achieve these goals, our team will include experts in thyroidology and rAAV biology and will involve collaborative efforts of the University of Florida and Medosome Biotec LLC. We anticipate that the discovery of this novel therapeutic approach to inhibit thyroid production and block TSAbs will be of considerable clinical importance and commercial potential.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2019	MEDOSOME BIOTEC LLC	3416 ASHWOOD DR	BLOOMINGTON	IN	47401	MONROE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	2/16/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $225,000 )
2019	2019	MEDOSOME BIOTEC LLC	3416 ASHWOOD DR	BLOOMINGTON	IN	47401	MONROE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	9/17/2019	NEW	$225,000
2019	2019	MEDOSOME BIOTEC LLC	3416 ASHWOOD DR	BLOOMINGTON	IN	47401	MONROE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	1	9/22/2019	NEW	$0
														Subtotal = $225,000

Grand Total All Awards = $225,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a Novel Therapeutic for Hyperthyroidism

Award Number: R41DK123953

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/17/2019

PERIOD OF PERFORMANCE END DATE: 08/31/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer